New product launch Opportunity to target acute migraine segment with ELYXYB, the FDA-approved ready-to-use celecoxib oral solution, as a key talking point for physicians treating migraine patients and for specialty pharmacies seeking a novel acute treatment option.

Chronic condition focus Position BDSI as a partner for chronic condition management leveraging BEMA technology to expand approved therapies; align with healthcare providers and payers interested in long-term, patient-centric delivery platforms.

Strategic partnerships Leverage past and potential collaborations to expand market reach; identify opportunities with distributors, payer networks, and specialty clinics that favor in-market therapies with differentiated delivery technologies.

Leadership continuity Capitalize on experienced executive team and recent C-suite appointments to instill investor and partner confidence; highlight stability and strategic execution when engaging potential corporate and financial partners.

Growth signals Revenue trajectory in the mid-range with a growing product portfolio and legacy acquisitions (e.g., Symproic) suggesting potential cross-sell and lifecycle management opportunities across neurology, pain, and inflammatory indications.